Enhanced Baseline Activity in the Left Ventromedial Putamen Predicts Individual Treatment Response in Drug-Naive, First-Episode Schizophrenia: Results from Two Independent Study Samples.

Huabing Li,Wenbin Guo,Feng Liu,Jindong Chen,Qinji Su,Zhikun Zhang,Xiaoduo Fan,Jingping Zhao
DOI: https://doi.org/10.1016/j.ebiom.2019.07.022
2019-01-01
SSRN Electronic Journal
Abstract:Background: Antipsychotic medications are the common treatment for schizophrenia. However, reliable biomarkers that can predict individual treatment response are still lacking. The present study aimed to examine whether baseline putamen activity can predict individual treatment response in schizophrenia. Methods: Two independent samples of patients with drug-naive, first-episode schizophrenia (32 patients in sample 1 and 44 in sample 2) and matched healthy controls underwent resting-state functional magnetic resonance imaging (fMR1) at baseline. Patients were treated with olanzapine for 8 weeks: symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and week 8. Fractional amplitude of low frequency fluctuation ( fALFF) and pattern classification techniques were used to analyze the data. Findings: Univariate analysis shows an elevated pre-treatment fALFF in the left ventromedial putamen in both patient samples compared to healthy controls (p's < 0.001). The support vector regression (SVR) analysis suggests a positive relationship between baseline pm-treatment fALFF in the left ventromedial putamen and improvement in positive symptom at week 8 in each patient group using a cross-validated method (r = 0.452, p = .002; r 0511, p = .003, respectively). Interpretation: Our study suggests that elevated pre-treatment mean fALFF in the left ventromedial putamen may predict individual therapeutic response to olanzapine treatment in drug-naive, first-episode patients with schizophrenia. Future studies are needed to confirm whether this finding is generalizable to patients with schizophrenia treated with other antipsychotic medications. (C) 2019 The Authors. Published by Elsevier B.V.
What problem does this paper attempt to address?